<p>Brummer Multi Strategy AB 在最近向证券交易委员会提交的文件中表示，在第四季度购买了 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - 免费报告) 的新头寸。这家机构投资者购买了 457,707 股该公司的股票，价值约为 1,488,000 美元。Maravai LifeSciences 约占 Brummer Multi Strategy AB 投资组合的 9.0%，使其成为第六大持仓。截至最近向证券交易委员会提交的文件，Brummer Multi Strategy AB 拥有 Maravai LifeSciences 约 0.18% 的股份。</p>
<p>获取 <strong>Maravai LifeSciences</strong> 的提醒：</p>
<p>其他机构投资者和对冲基金也买卖了该公司的股票。Tejara Capital Ltd 在第三季度将其在 Maravai LifeSciences 的持股增加了 26.4%。Tejara Capital Ltd 现在拥有 2,453,441 股该公司的股票，价值 7,041,000 美元，此前在上个季度又收购了 511,992 股。Monaco Asset Management SAM 在第三季度将其在 Maravai LifeSciences 的持股增加了 315.0%。Monaco Asset Management SAM 现在拥有 3,656,337 股该公司的股票，价值 10,494,000 美元，此前在上个季度又收购了 2,775,372 股。First Eagle Investment Management LLC 在第三季度收购了 Maravai LifeSciences 的新头寸，价值约为 1,294,000 美元。Royce &amp; Associates LP 在第三季度将其在 Maravai LifeSciences 的持仓增加了 38.0%。Royce &amp; Associates LP 现在拥有 1,761,764 股该公司的股票，价值 5,056,000 美元，此前在上个季度又购买了 484,908 股。最后，General American Investors Co. Inc. 在第三季度收购了 Maravai LifeSciences 的新头寸，价值约为 391,000 美元。机构投资者拥有该公司 50.25% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师对 MRVI 股票发表了看法。德意志银行重申了对 Maravai LifeSciences 的 “买入” 评级，并在周五的研究报告中设定了 6.00 美元的目标价。富国银行将 Maravai LifeSciences 的目标价从 4.50 美元上调至 5.50 美元，并在周五的研究报告中给予该股票 “超配” 评级。最后，Wall Street Zen 在 2 月 28 日的研究报告中将 Maravai LifeSciences 的评级从 “卖出” 上调至 “持有”。四位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 5.70 美元。</p>
<p><strong>查看我们对 Maravai LifeSciences 的最新分析</strong></p>
<h2>Maravai LifeSciences 股票表现</h2>
<p>NASDAQ:MRVI 的股票周一开盘价为 4.85 美元。该公司的市值为 12.5 亿美元，市盈率为 -6.83，贝塔值为 0.62。Maravai LifeSciences Holdings, Inc. 的一年最低价为 1.95 美元，一年最高价为 4.95 美元。该公司的债务与股本比率为 0.85，流动比率为 6.60，速动比率为 5.69。该业务的 50 日简单移动平均线为 3.33 美元，200 日简单移动平均线为 3.39 美元。</p>
<p>Maravai LifeSciences (NASDAQ:MRVI - 获取免费报告) 最近在 5 月 7 日发布了季度财报。该公司报告每股收益 (EPS) 为 0.01 美元，超出分析师的共识预期（-0.05 美元）0.06 美元。该业务在本季度的收入为 6,584 万美元，而共识预期为 5,300 万美元。Maravai LifeSciences 的股本回报率为 -17.29%，净利润率为 -51.07%。研究分析师预计，Maravai LifeSciences Holdings, Inc. 在当前财政年度将发布 -0.26 的每股收益。</p>
<h2>关于 Maravai LifeSciences</h2>
<p>(免费报告)</p>
<p>Maravai LifeSciences Holdings, Inc NASDAQ: MRVI 是一家生命科学公司，专注于开发和提供生物治疗开发和生产所需的关键试剂和服务。该公司的产品支持基因组学、分子诊断、疫苗开发和下一代测序等多种应用。Maravai 的平台解决了生物制药行业中核酸生产、蛋白质检测、表观遗传分析和试剂质量等关键挑战。</p>
<p>通过其产品组合，包括专有的 mRNA 封闭试剂、脂质纳米颗粒递送系统、合成寡核苷酸和高精度检测工具，Maravai 使客户能够加速研究并简化制造工作流程。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Maravai LifeSciences</li>
<li>超越 NVIDIA：强劲势头的 AI 相关股票推荐</li>
<li>量子财报季正在升温——关注两大主要参与者的动态</li>
<li>Flutter 在财报后看到提升，FanDuel 显示复苏迹象</li>
<li>3 只医疗保健股票将从一项重大法案中受益</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJWSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJWSQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Maravai LifeSciences 吗？</h2>
<p>在你考虑 Maravai LifeSciences 之前，你会想听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Maravai LifeSciences 并不在名单上。</p>
<p>虽然 Maravai LifeSciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看五只股票</p>

MRVI

动态生物技术与基因组 ETF - Invesco

IBBQ

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

<p>Brummer Multi Strategy AB 在第四季度收购了 457,707 股 Maravai LifeSciences Holdings, Inc.（纳斯达克代码：MRVI），价值约为 149 万美元，使其成为其投资组合中第六大持仓。其他机构投资者也增加了对 Maravai 的持股。分析师对 MRVI 的一致评级为 “适度买入”，目标价为 5.70 美元。Maravai 报告的季度每股收益为 0.01 美元，超出预期，收入为 6584 万美元。该股票开盘价为 4.85 美元，市值为 12.5 亿美元</p>

<p>Brummer Multi Strategy AB bought a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor bought 457,707 shares of the company's stock, valued at approximately $1,488,000. Maravai LifeSciences makes up approximately 9.0% of Brummer Multi Strategy AB's portfolio, making the stock its 6th largest position. Brummer Multi Strategy AB owned about 0.18% of Maravai LifeSciences as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>Brummer Multi Strategy AB 在最近向证券交易委员会提交的文件中表示，在第四季度购买了 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - 免费报告) 的新头寸。这家机构投资者购买了 457,707 股该公司的股票，价值约为 1,488,000 美元。Maravai LifeSciences 约占 Brummer Multi Strategy AB 投资组合的 9.0%，使其成为第六大持仓。截至最近向证券交易委员会提交的文件，Brummer Multi Strategy AB 拥有 Maravai LifeSciences 约 0.18% 的股份。</p>
</div><p>Get <strong>Maravai LifeSciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Maravai LifeSciences</strong> 的提醒：</p>
</div><p>Other institutional investors and hedge funds have also bought and sold shares of the company. Tejara Capital Ltd raised its holdings in Maravai LifeSciences by 26.4% during the third quarter. Tejara Capital Ltd now owns 2,453,441 shares of the company's stock worth $7,041,000 after acquiring an additional 511,992 shares in the last quarter. Monaco Asset Management SAM raised its holdings in Maravai LifeSciences by 315.0% during the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company's stock worth $10,494,000 after acquiring an additional 2,775,372 shares in the last quarter. First Eagle Investment Management LLC acquired a new position in Maravai LifeSciences during the third quarter worth approximately $1,294,000. Royce &amp; Associates LP increased its position in Maravai LifeSciences by 38.0% during the third quarter. Royce &amp; Associates LP now owns 1,761,764 shares of the company's stock worth $5,056,000 after buying an additional 484,908 shares during the last quarter. Finally, General American Investors Co. Inc. acquired a new position in Maravai LifeSciences during the third quarter worth approximately $391,000. Institutional investors own 50.25% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也买卖了该公司的股票。Tejara Capital Ltd 在第三季度将其在 Maravai LifeSciences 的持股增加了 26.4%。Tejara Capital Ltd 现在拥有 2,453,441 股该公司的股票，价值 7,041,000 美元，此前在上个季度又收购了 511,992 股。Monaco Asset Management SAM 在第三季度将其在 Maravai LifeSciences 的持股增加了 315.0%。Monaco Asset Management SAM 现在拥有 3,656,337 股该公司的股票，价值 10,494,000 美元，此前在上个季度又收购了 2,775,372 股。First Eagle Investment Management LLC 在第三季度收购了 Maravai LifeSciences 的新头寸，价值约为 1,294,000 美元。Royce &amp; Associates LP 在第三季度将其在 Maravai LifeSciences 的持仓增加了 38.0%。Royce &amp; Associates LP 现在拥有 1,761,764 股该公司的股票，价值 5,056,000 美元，此前在上个季度又购买了 484,908 股。最后，General American Investors Co. Inc. 在第三季度收购了 Maravai LifeSciences 的新头寸，价值约为 391,000 美元。机构投资者拥有该公司 50.25% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts have weighed in on MRVI shares. Deutsche Bank Aktiengesellschaft reissued a &#34;buy&#34; rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday. Wells Fargo &amp; Company boosted their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the stock an &#34;overweight&#34; rating in a research report on Friday. Finally, Wall Street Zen raised Maravai LifeSciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, February 28th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $5.70.</p>
<div class="lb-trans"><p>一些股票分析师对 MRVI 股票发表了看法。德意志银行重申了对 Maravai LifeSciences 的 “买入” 评级，并在周五的研究报告中设定了 6.00 美元的目标价。富国银行将 Maravai LifeSciences 的目标价从 4.50 美元上调至 5.50 美元，并在周五的研究报告中给予该股票 “超配” 评级。最后，Wall Street Zen 在 2 月 28 日的研究报告中将 Maravai LifeSciences 的评级从 “卖出” 上调至 “持有”。四位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 5.70 美元。</p>
</div><p><strong>View Our Latest Analysis on Maravai LifeSciences</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Maravai LifeSciences 的最新分析</strong></p>
</div><h2>Maravai LifeSciences Stock Performance</h2>
<div class="lb-trans"><h2>Maravai LifeSciences 股票表现</h2>
</div><p>Shares of NASDAQ:MRVI opened at $4.85 on Monday. The company has a market capitalization of $1.25 billion, a P/E ratio of -6.83 and a beta of 0.62. Maravai LifeSciences Holdings, Inc. has a 1 year low of $1.95 and a 1 year high of $4.95. The company has a debt-to-equity ratio of 0.85, a current ratio of 6.60 and a quick ratio of 5.69. The business's 50 day simple moving average is $3.33 and its 200 day simple moving average is $3.39.</p>
<div class="lb-trans"><p>NASDAQ:MRVI 的股票周一开盘价为 4.85 美元。该公司的市值为 12.5 亿美元，市盈率为 -6.83，贝塔值为 0.62。Maravai LifeSciences Holdings, Inc. 的一年最低价为 1.95 美元，一年最高价为 4.95 美元。该公司的债务与股本比率为 0.85，流动比率为 6.60，速动比率为 5.69。该业务的 50 日简单移动平均线为 3.33 美元，200 日简单移动平均线为 3.39 美元。</p>
</div><p>Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.06. The business had revenue of $65.84 million for the quarter, compared to the consensus estimate of $53.00 million. Maravai LifeSciences had a negative return on equity of 17.29% and a negative net margin of 51.07%. On average, research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.26 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Maravai LifeSciences (NASDAQ:MRVI - 获取免费报告) 最近在 5 月 7 日发布了季度财报。该公司报告每股收益 (EPS) 为 0.01 美元，超出分析师的共识预期（-0.05 美元）0.06 美元。该业务在本季度的收入为 6,584 万美元，而共识预期为 5,300 万美元。Maravai LifeSciences 的股本回报率为 -17.29%，净利润率为 -51.07%。研究分析师预计，Maravai LifeSciences Holdings, Inc. 在当前财政年度将发布 -0.26 的每股收益。</p>
</div><h2>About Maravai LifeSciences</h2>
<div class="lb-trans"><h2>关于 Maravai LifeSciences</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.</p>
<div class="lb-trans"><p>Maravai LifeSciences Holdings, Inc NASDAQ: MRVI 是一家生命科学公司，专注于开发和提供生物治疗开发和生产所需的关键试剂和服务。该公司的产品支持基因组学、分子诊断、疫苗开发和下一代测序等多种应用。Maravai 的平台解决了生物制药行业中核酸生产、蛋白质检测、表观遗传分析和试剂质量等关键挑战。</p>
</div><p>Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.</p>
<div class="lb-trans"><p>通过其产品组合，包括专有的 mRNA 封闭试剂、脂质纳米颗粒递送系统、合成寡核苷酸和高精度检测工具，Maravai 使客户能够加速研究并简化制造工作流程。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Maravai LifeSciences</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Maravai LifeSciences</li>
<li>超越 NVIDIA：强劲势头的 AI 相关股票推荐</li>
<li>量子财报季正在升温——关注两大主要参与者的动态</li>
<li>Flutter 在财报后看到提升，FanDuel 显示复苏迹象</li>
<li>3 只医疗保健股票将从一项重大法案中受益</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJWSQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MRVI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Maravai LifeSciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Maravai LifeSciences 吗？</h2>
</div><p>Before you consider Maravai LifeSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Maravai LifeSciences 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Maravai LifeSciences 并不在名单上。</p>
</div><p>While Maravai LifeSciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Maravai LifeSciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看五只股票</p>
</div>

457,707 Shares in Maravai LifeSciences Holdings, Inc. $MRVI Purchased by Brummer Multi Strategy AB

Market Beat

Maravai LifeSciences

Invesco Nasdaq Biotechnology ETF

德意志银行

富国银行

英伟达

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

NVIDIA Corporation

Brummer Multi Strategy AB 购入了 457,707 股 Maravai LifeSciences Holdings, Inc.（股票代码：$MRVI）的股票